{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:56:20Z","timestamp":1788350180202,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Retinal vein occlusion (RVO) represents a common ophthalmological disorder that, if untreated, often leads to severely impaired vision. The classic vascular risk factors, aging and glaucoma, represent the core pathogenic factors for RVO. However, antiphospholipid syndrome (APS) has been involved in a non-negligible number of patients with RVO. The main objective of the present study was to assess the performance of the new 2023 ACR\/EULAR classification criteria for APS in a cohort of patients with RVO fulfilling the Sydney classification criteria. Methods: A prospective study of consecutive patients with RVO diagnosed with APS in a third-level university hospital. The new 2023 ACR\/EULAR classification criteria for APS were applied to all patients. Vascular risk factors, the antiphospholipid antibody (aPL) profile, clinical management, and clinical outcomes were assessed and compared between those fulfilling the Sydney and the 2023 ACR\/EULAR criteria. Results: Sixty-nine RVO-APS patients were included in the study. After applying the new classification criteria, 18 patients (26.1%) did not fulfill the new criteria for APS. Specifically, 17 (24.6%) were excluded due to the new Domain 8 (p &lt; 0.001) as they presented only aPL IgM serology, and 1 patient (1.4%) was excluded due to having high venous thromboembolic risk (VTE) with a clinical domain score &lt; 3. Interestingly enough, the presence of high arterial risk (45.1% vs. 50%; p = 0.72) was greater than the presence of high VTE (3.9% vs. 5.6%; p = 0.99); in both cases, the 51 RVO-APS patients were classified with the 2023 ACR\/EULAR criteria, and the 18 cases were excluded according to the new classification criteria. Except for the expected differences in serological domains (Domain 7, p &lt; 0.001, and Domain 8, p &lt; 0.001), we did not find other significant differences in terms of prognosis or risk of recurrence between both groups of patients. Conclusions: The implementation of the new ACR\/EULAR 2023 classification criteria for APS resulted in the exclusion of about one out of four previously diagnosed RVO-APS patients. The higher prevalence of manifestations of high arterial risk compared with high VTE among both newly classified and excluded APS patients highlights the importance of monitoring cardiovascular risk factors for both the prevention and the management of potential retinal and cardiovascular events.<\/jats:p>","DOI":"10.3390\/jcm14082826","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T20:24:16Z","timestamp":1745180656000},"page":"2826","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of the 2023 ACR\/EULAR Antiphospholipid Syndrome Criteria on Retinal Vein Occlusion Patients"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9525-2947","authenticated-orcid":false,"given":"Rafael","family":"G\u00e1lvez-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-2900","authenticated-orcid":false,"given":"Zaida","family":"Salm\u00f3n Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1780-8239","authenticated-orcid":false,"given":"Andrea","family":"Cerver\u00f3 Varona","sequence":"additional","affiliation":[{"name":"Division of Ophtalmology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Gonz\u00e1lez-Mesones","sequence":"additional","affiliation":[{"name":"Division of Hematology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-427X","authenticated-orcid":false,"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[{"name":"Division of Inmunology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-8491","authenticated-orcid":false,"given":"V\u00edctor","family":"Mart\u00ednez-Taboada","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"},{"name":"Departamento de Medicina y Psiquiatr\u00eda, Universidad de Cantabria, 39005 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-8847","authenticated-orcid":false,"given":"Jos\u00e9","family":"Luis Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de Investigaci\u00f3n Valdecilla, 39008 Santander, Spain"},{"name":"Departamento de Medicina y Psiquiatr\u00eda, Universidad de Cantabria, 39005 Santander, Spain"},{"name":"Department of Internal Medicine, Hospital Marqu\u00e9s de Valdecilla-IDIVAL, Avda. Valdecilla s\/n, 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2006.06.061","article-title":"Retinal Vein Occlusion and Vascular Mortality","volume":"114","author":"Cugati","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/archopht.126.5.692","article-title":"Retinal Vein Occlusion and Traditional Risk Factors for Atherosclerosis","volume":"126","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.rce.2013.01.012","article-title":"Trombofilia y factores de riesgo vascular en la obstrucci\u00f3n venosa retiniana","volume":"213","year":"2013","journal-title":"Rev. Clin. Esp."},{"key":"ref_4","first-page":"e692","article-title":"Association of glaucoma with risk of retinal vein occlusion: A meta-analysis","volume":"96","author":"Zhou","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.medcli.2023.04.027","article-title":"Retinal vein occlusion in the general population after COVID-19 vaccination and infection","volume":"161","author":"Napal","year":"2023","journal-title":"Med. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities","volume":"33","author":"Rehak","year":"2008","journal-title":"Curr. Eye Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and Associations of Retinal Vein Occlusion in Australia","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0161-6420(93)31633-7","article-title":"Arteriovenous Crossing Patterns in Branch Retinal Vein Occlusion","volume":"100","author":"Zhao","year":"1993","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1442-9071.1993.tb00959.x","article-title":"An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions","volume":"21","author":"Jefferies","year":"1993","journal-title":"Aust. N. Z. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1160\/TH09-05-0331","article-title":"Coagulation disorders and the risk of retinal vein occlusion","volume":"103","author":"Scharrer","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1160\/TH09-09-0626","article-title":"Antithrombotic and fibrinolytic drugs for retinal vein occlusion: A systematic review and a call for action","volume":"103","author":"Squizzato","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjo.2010.182857","article-title":"Ocular manifestations of the antiphospholipid syndrome","volume":"95","author":"Utz","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.medcli.2024.01.048","article-title":"Oclusi\u00f3n venosa de retina y su asociaci\u00f3n con la enfermedad vascular ateroscler\u00f3tica","volume":"163","year":"2024","journal-title":"Med. Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2020.04.005","article-title":"Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion","volume":"190","author":"Olmos","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2022.11.009","article-title":"Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion","volume":"221","author":"Napal","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/rheumatology\/kez596","article-title":"Identifying phenotypes of patients with antiphospholipid antibodies: Results from a cluster analysis in a large cohort of patients","volume":"60","author":"Sciascia","year":"2021","journal-title":"Rheumatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.eye.6700685","article-title":"Central retinal vein and ophthalmic artery occlusion in primary antiphospholipid syndrome","volume":"18","author":"Yap","year":"2004","journal-title":"Eye"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2022). Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes. Diabetes Care, 45, S17\u2013S38.","DOI":"10.2337\/dc22-S002"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2012-203101","article-title":"Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: Results of a population-based study","volume":"73","author":"Corrales","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000097034","article-title":"Mannheim Carotid Intima-Media Thickness Consensus (2004\u20132006)","volume":"23","author":"Touboul","year":"2007","journal-title":"Cerebrovasc. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12016-021-08915-9","article-title":"Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study","volume":"63","author":"Merino","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/rheumatology\/keae058","article-title":"2023 ACR\/EULAR classification criteria in existing research cohorts: An international study","volume":"63","author":"Foddai","year":"2024","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/art.42835","article-title":"A diagnostic performance study of the 2023 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for patients with antiphospholipid syndrome from the Antiphospholipid Syndrome Chinese Collaborative cohort presenting with suspected antiphospholipid syndrome","volume":"76","author":"Lu","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e15175","DOI":"10.1111\/1756-185X.15175","article-title":"Assessment and comparison of the 2023 ACR\/EULAR APS criteria with the revised Sapporo criteria","volume":"27","author":"Vasi","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/rheumatology\/keae214","article-title":"Setting the bar differently: How to navigate old and new sets of criteria for the classification of antiphospholipid syndrome","volume":"63","author":"Tincani","year":"2024","journal-title":"Rheumatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2004.10.045","article-title":"An evaluation of image quality and accuracy of eye bank measurement of donor cornea endothelial cell density in the Specular Microscopy Ancillary Study","volume":"112","author":"Lass","year":"2005","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archophthalmol.2011.2","article-title":"Myocardial Infarction and Cerebrovascular Accident in Patients With Retinal Vein Occlusion","volume":"129","author":"Werther","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OPTH.S7631","article-title":"Retinal vein occlusion: Pathophysiology and treatment options","volume":"4","author":"Karia","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/bjo.69.7.493","article-title":"Medical conditions underlying recurrence of retinal vein occlusion","volume":"69","author":"Dodson","year":"1985","journal-title":"Br. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archopht.124.5.726","article-title":"Ten-Year Incidence of Retinal Vein Occlusion in an Older Population","volume":"124","author":"Cugati","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1160\/TH04-11-0768","article-title":"Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?","volume":"93","author":"Janssen","year":"2005","journal-title":"Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/107602969900500206","article-title":"State-of-the-Art Review: Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan","volume":"5","author":"Mori","year":"1999","journal-title":"Clin. Appl. Thromb.\/Hemost."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2826\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:01Z","timestamp":1760030281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082826"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082826","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}